| Assessment Status | Rapid Review Complete |
| HTA ID | 25011 |
| Drug | Rucaparib |
| Brand | Rubraca® |
| Indication | Rucaparib (Rubraca®) is indicated as monotherapy for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy. |
| Assessment Process | |
| Rapid review commissioned | 17/02/2025 |
| Rapid review completed | 24/03/2025 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that rucaparib not be considered for reimbursement at the submitted price*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
Next steps: The NCPE Assessment Report and recommendation, will be considered by the HSE when making their decision on reimbursement, while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
Further information on this process may be found here.
Further information on the status of this decision may be found here.
